

miR-145 and miR-143 regulate smooth muscle cell fate and plasticity

Kimberly R. Cordes^{1,2,3}, Neil T. Sheehy^{1,2,3}, Mark P. White^{1,2,3}, Emily C. Berry^{1,2,3}, Sarah U. Morton^{1,2,3}, Alecia N. Muth^{1,2,3}, Ting-Hein Lee⁴, Joseph M. Miano⁴, Kathryn N. Ivey^{1,2,3} & Deepak Srivastava^{1,2,3}

MicroRNAs (miRNAs) are regulators of myriad cellular events, but evidence for a single miRNA that can efficiently differentiate multipotent stem cells into a specific lineage or regulate direct reprogramming of cells into an alternative cell fate has been elusive. Here we show that miR-145 and miR-143 are co-transcribed in multipotent murine cardiac progenitors before becoming localized to smooth muscle cells, including neural crest stem-cell-derived vascular smooth muscle cells. miR-145 and miR-143 were direct transcriptional targets of serum response factor, myocardin and Nkx2-5 (NK2 transcription factor related, locus 5) and were downregulated in injured or atherosclerotic vessels containing proliferating, less differentiated smooth muscle cells. miR-145 was necessary for myocardin-induced reprogramming of adult fibroblasts into smooth muscle cells and sufficient to induce differentiation of multipotent neural crest stem cells into vascular smooth muscle. Furthermore, miR-145 and miR-143 cooperatively targeted a network of transcription factors, including Klf4 (Kruppel-like factor 4), myocardin and Elk-1 (ELK1, member of ETS oncogene family), to promote differentiation and repress proliferation of smooth muscle cells. These findings demonstrate that miR-145 can direct the smooth muscle fate and that miR-145 and miR-143 function to regulate the quiescent versus proliferative phenotype of smooth muscle cells.

MicroRNAs represent a class of small (~20–25 nucleotides), non-coding RNAs that are key regulators of many cellular events, including the balance between proliferation and differentiation during tumorigenesis and organ development^{1–3}. MicroRNAs are initially transcribed as longer primary transcripts (pri-miRNAs) and processed first by the RNase enzyme complex, Drosha–DGCR8, and then by Dicer, leading to incorporation of a single strand into the RNA-induced silencing complex. Each of the ~650 human miRNAs is predicted to interact with more than 100 target mRNAs in a sequence-specific fashion involving Watson–Crick base-pairing among nucleotides 2–8 of the miRNA^{4,5}. MicroRNAs generally inhibit target messenger RNAs by repressing translation or reducing mRNA stability. MicroRNAs may also activate mRNA translation under certain cellular conditions⁶.

Regulation of cardiovascular cell fate decisions by miRNAs and control of proliferation and differentiation in cardiac progenitors have been reported, but remain inefficient^{7–12}. A multipotent cardiac progenitor pool that can differentiate into cardiac myocytes, vascular smooth muscle cells (VSMCs) and endothelial cells exists¹³, as do multipotent neural crest stem cells that can also give rise to VSMCs, as well as melanocytes, chondrocytes and neurons¹⁴. Among these cell types, VSMCs are uniquely plastic, as they can oscillate between a proliferative or a quiescent, more differentiated state¹⁵. This plasticity contributes to many human vascular diseases, including atherosclerosis^{16,17}. The transcriptional control of this oscillation has been described¹⁶, but whether VSMC-enriched miRNAs exist or participate in this process is unknown. Here we demonstrate that miR-145 and miR-143 are tightly integrated into a core transcriptional network involved in smooth muscle differentiation and proliferation, and that miR-145 functions as a critical switch in promoting smooth muscle differentiation.

miR-143 and miR-145 expression

We reported that miR-143 is the most enriched miRNA during differentiation of mouse embryonic stem (ES) cells into multipotent cardiac progenitors¹¹. *miR-143* is highly conserved and lies within 1.7 kilobases (kb) of another conserved miRNA, *miR-145*, on mouse chromosome 18 (Supplementary Fig. 1a, b). Both miRNAs are downregulated in various cancer cell lines, colon cancers, and lung cancers². Given their genomic organization and proximity, *miR-143* and *miR-145* may be contained in a bicistronic primary transcript, but we were unable to amplify a common transcript from RNA, possibly because pri-miRNA transcripts are rapidly processed into their mature forms. *DGCR8*-null ES cells lack nuclear miRNA processing activity and have a defect in differentiation¹⁸, but can form mesoderm. Using primers for each miRNA and RNA from *DGCR8*-null embryoid bodies (EBs), we generated an amplicon that encompassed both miRNAs (Supplementary Fig. 1b), suggesting that *miR-143* and *miR-145* were transcribed as a bicistronic unit and therefore share common regulatory elements that control their expression.

To determine if these two miRNAs are also enriched in multipotent cardiac progenitors *in vivo*, we bred transgenic mice containing *Cre recombinase* in the *Islet1* locus¹⁹ with *Rosa26-EYFP* mice²⁰, and isolated YFP⁺ cardiac progenitor cells at embryonic day (E)9.5 by fluorescence-activated cell sorting (FACS) (Supplementary Fig. 1c, d). The *Islet1-Cre* mice mark early multipotent cardiac progenitor cells that can differentiate into cardiac muscle, smooth muscle and endothelial cells²¹. Quantitative RT–PCR (qPCR) revealed that miR-143 and miR-145 were enriched in YFP⁺ cells (Supplementary Fig. 1e). qPCR with RNA from mouse hearts or whole embryos at varying stages of development also revealed enrichment of both miRNAs throughout cardiogenesis, before being downregulated in the adult heart (Supplementary Fig. 1f, g).

¹Gladstone Institute of Cardiovascular Disease, San Francisco, California 94158, USA. ²Department of Pediatrics, University of California, San Francisco, California 94543, USA.

³Department of Biochemistry & Biophysics, University of California, San Francisco, California 94143, USA. ⁴Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.

Transcriptional regulation of *miR-143/miR-145*

To identify the tissue-specific expression and regulation of *miR-143/miR-145* during mouse development, we searched for upstream regulatory regions. Comparison of genomic sequences across species revealed a 4.2-kb genomic region upstream of *miR-143/miR-145* that was highly conserved between human and mouse (Supplementary Fig. 2a) and directed LacZ reporter expression specifically in multipotent cardiac mesodermal progenitors of transgenic mice as early as E7.5 (Fig. 1a, b). By E9.5, LacZ expression was more robust and uniform in the heart and outflow tract and in cardiac progenitors of the pharyngeal mesoderm; expression was also present in the aorta just as smooth muscle differentiation began, but was absent in the cardinal vein (Fig. 1c, d). LacZ expression was robust in the endocardium and myocardium (Fig. 1d). During later cardiogenesis, expression became restricted to the ventricles and atria, but was notably absent in the aorta and pulmonary arteries (Fig. 1e). Postnatally, the pattern was reversed, with high transcript levels in smooth muscle of the aorta, pulmonary artery and coronary vessels but undetectable levels in the ventricular myocardium (Fig. 1f–h). This enhancer was also active in the smooth muscle of the intestines (Supplementary Fig. 2b, c). The enhancer recapitulated the endogenous *miR-145* expression, with transcripts in the smooth muscle of the adult aorta and coronary artery, but not ventricular myocardium, as shown by section *in situ* hybridization (Fig. 1i, j and Supplementary Fig. 2d).

Deletions of the 4.2-kb *miR-143/miR-145* enhancer revealed that a 0.9-kb region was sufficient for *miR-143/miR-145* cardiac and




Figure 1 | *miR-143* and *miR-145* are cardiac-specific and smooth-muscle-specific miRNAs. a–c, Whole mounts showing cardiac-specific β -gal activity in transgenic mouse embryos with a 4.2-kb enhancer-lacZ construct (Supplementary Fig. 2a) at indicated time points. d, Transverse section of c showing β -gal expression in pharyngeal mesoderm (pm), pharyngeal endoderm (pe), dorsal aorta (da), myocardium (mc), endocardium (ec). e, f, β -gal expression in E15.5 (e) or post-natal day (P)21 (f) heart. Scale bars: 200 μ m (a, b), 100 μ m (c–e), 1 mm (f). Ao, aorta; pa, pulmonary artery. g, h, Transverse sections of f; co, coronary artery. i, j, Section *in situ* hybridization of *miR-145* in P21 heart section. Scale bars: 500 μ m (g, i), 100 μ m (h, j). Inset in h highlights co. Panels h and j represent higher magnification of boxed areas. pcm, precardiac mesoderm; ht, heart; h, head; ot, outflow tract; rv, right ventricle; lv, left ventricle; cv., cardinal vein; ra, right atrium; la, left atrium; vs, ventricular septum.

2

smooth muscle expression (Fig. 2a–e, Supplementary Fig. 3a). Within this regulatory region, we observed *cis* elements highly conserved between human, mouse and zebrafish that represented potential binding sites for the essential cardiac transcription factors, serum response factor (SRF) and Nkx2-5 (Supplementary Fig. 3b). SRF plays a dual role in cardiac and VSMC development, influencing both proliferation and differentiation depending on the types of co-activators or repressors present at specific developmental or cellular stages²². The potent SRF co-activator, myocardin (Myocd)²³, is a component of a molecular switch for the VSMC fate²⁴ and is sufficient to effect both structural and physiological attributes of this cell type²⁵. SRF weakly activated the *miR-143/miR-145* enhancer upstream of a luciferase reporter, but co-transfection of Myocd synergistically and robustly activated luciferase activity in Cos cells (Fig. 2f). Mutation of the highly conserved CArG box in the SRF binding site decreased Myocd-dependent luciferase activity (Fig. 2f). Nkx2-5 could also independently activate this enhancer, and the combination of SRF, Myocd and Nkx2-5, which also interacts with SRF²⁶, had additive effects on luciferase activity. Mutation of each binding site progressively decreased luciferase activity (Fig. 2f).

In vivo, mutation of the SRF binding site disrupted lacZ expression in the outflow tract and aorta, while disruption of the Nkx2-5 binding site diminished expression in the ventricles and atria (Fig. 2c, d), suggesting modular regulation by the enhancer. Mutation of both the SRF and Nkx2-5 binding sites abolished all activity of the enhancer within the heart (Fig. 2e). VSMC and atrial expression postnatally was also dependent upon the SRF-binding *cis* element (Supplementary Fig. 3c). Electromobility shift assay confirmed that SRF could specifically bind to the putative binding site in the *miR-143/miR-145* enhancer (Supplementary Fig. 3d). Furthermore, *miR-143* and *miR-145* were each expressed at lower levels in SRF-null EBs compared to wild-type EBs derived from the respective ES cells (Fig. 2g). The levels were also reduced in mesoderm-rescued SRF-null EBs¹¹, confirming that the decreases did not reflect the absence of mesoderm (Fig. 2g). Similarly, *miR-143* and *miR-145* expression was also decreased in hearts of Nkx2-5 mutant mouse embryos in a dose-dependent fashion (Fig. 2h).

Dysregulation in vascular disease

The dynamic stage-dependent expression of *miR-143* and *miR-145* raised the possibility that their expression may also vary with the oscillation of VSMCs between differentiated and proliferative phenotypes. In a mouse model of this proliferative switch, ligation of the carotid arteries typically results in narrowing of the vascular lumen as a result of phenotypic modulation and proliferation of VSMCs. qPCR revealed marked decreases in *miR-143* and *miR-145* expression in injured carotid arteries compared to contralateral control vessels (Fig. 2i). *miR-21* expression was increased as expected²⁷, and *miR-16* was unchanged, demonstrating the presence of intact small RNAs. *In situ* hybridization of injured and control carotid arteries also revealed marked downregulation of *miR-143* and *miR-145* expression in the thickened vascular wall, coincident with decreased expression of the differentiation marker, smooth muscle α -actin (Sm- α -actin) (Supplementary Fig. 4a). As a control, *miR-143* and *miR-145* levels were unchanged in cardiac muscle after injury (Supplementary Fig. 4b). Interestingly, transcripts of *miR-145* were also downregulated to nearly undetectable levels in atherosclerotic lesions containing neointimal hyperplasia (Fig. 2j).

Regulation of cell fate and proliferation

The bimodal expression of *miR-143* and *miR-145* early during VSMC induction, and subsequently during the maturation into a non-proliferating, differentiated phenotype, led us to investigate their potential function in these settings. As *miR-145* and *miR-143* expression was directly activated by SRF-Myocd, we first investigated whether expression of either miRNA was necessary for Myocd-induced




Figure 2 | SRF and Nkx2-5 directly regulate cardiac and smooth muscle expression of miR-143 and miR-145. **a–e**, Lateral (**a–c**, **e**) or frontal (**d**) cardiac views of transgenic embryos containing indicated wild type (WT) or mutant (mt) lacZ constructs and stained for β -Gal activity. **f**, Fold-activation of luciferase activity directed by introduction of SRF, Myocd or Nkx2-5 expression vectors with the miR-143/145 enhancer in Cos cells. All changes were statistically significant with $P < 0.05$ ($n = 5$). **g**, miR-143 and miR-145 expression levels assessed by qPCR on day 10 embryoid bodies

reprogramming of fibroblasts into VSMCs. Introduction of 1–2 μ g of Myocd into fibroblasts reliably resulted in $>50\%$ conversion to VSMCs²². Inhibition of miR-145 using cholesterol-modified antisense oligonucleotides (antagomirs)²⁸ blocked Myocd's ability to convert fibroblasts into VSMCs, as illustrated by Sm- α -actin immunostaining and expression of multiple smooth muscle markers assessed by qPCR and western blot (Fig. 3a–c, e). The knockdown of miR-143 had little effect on Myocd-induced smooth muscle conversion (Fig. 3a, b and Supplementary Fig. 5a, b). Neither miRNA was sufficient to reprogram fibroblast cells. However, miR-145 potentiated Myocd's reprogramming effects. Although 50 ng of Myocd was insufficient to induce VSMC gene expression, simultaneous addition of miR-145, but not miR-143, resulted in robust VSMC differentiation, equivalent to that observed with 1–2 μ g of Myocd (Fig. 3b, d, e and Supplementary Fig. 5c). Thus, miR-145 activity was required for Myocd-dependent conversion of fibroblasts into VSMCs, and miR-145 robustly potentiated Myocd's effects.

To test an alternative cell type in which miR-145 may be sufficient for VSMC differentiation, we used a multipotent neural crest stem cell line that can differentiate into numerous cell types (for example, melanocytes, chondrocytes, neurons), including VSMCs, on exposure to 5 days of TGF- β ²⁹. Remarkably, introduction of miR-145, but not miR-143, into neural crest stem cells was sufficient to guide $\sim 75\%$ of cells into the VSMC lineage within only 24 hours, as determined by immunocytochemistry with multiple markers (Fig. 3f). qPCR and western blot revealed upregulation of numerous markers

(EBs) of indicated genotypes. **h**, qPCR of miR-143 and miR-145 in Nkx2-5^{+/-} and Nkx2-5^{-/-} E9.5 hearts relative to wild type. **i**, **j**, qPCR of miRNAs in injured vessels (**i**) or atherosclerotic lesions (**j**) compared to normal arterial expression. Results shown in (**g–j**) are from three experiments. ot, outflow tract; ra, right atrium; lv, left ventricle; rv, right ventricle; la, left atrium; da, dorsal aorta. NS, not significant; * $P < 0.05$; error bars, s.d. Scale bars: 50 μ m.

of VSMC differentiation, including Sm- α -actin, Sm-22 α , and smooth muscle myosin heavy chain (Sm-MHC) by miR-145 but not miR-143 (Fig. 3g, h; Supplementary Fig. 5d, e). The neural crest stem-cell-derived VSMCs exhibited calcium flux measurements similar to cultured VSMCs in response to endothelin-1 stimulation, indicating the differentiation of functionally mature smooth muscle (Fig. 3i). Thus, miR-145 was sufficient for directing the VSMC fate from multipotent neural crest stem cells that normally populate the aortic smooth muscle tissue, where miR-145 is expressed.

miRNA targets and mechanism

The mechanism by which these miRNAs regulate VSMCs is dependent on their mRNA targets. A bioinformatics approach, incorporating sequence matching and mRNA secondary structure to predict mRNA targets (K.N.I. and D.S., unpublished results; also see Methods), revealed multiple highly conserved binding sites for miR-143 in the 3' untranslated region (UTR) of *Elk-1* and for miR-145 in the 3' UTR of *Myocd* (Supplementary Fig. 6a). Growth signals repress smooth muscle gene expression by displacing Myocd from SRF with Elk-1, a ternary complex factor that acts as a myogenic repressor and an activator of VSMC proliferation²². In this system, SRF serves as a platform for myogenic coactivators or corepressors that compete for a common docking site, thereby mediating VSMC phenotypic switching.

To determine whether Elk-1 and Myocd are direct targets of miR-143 or miR-145, respectively, we cloned the 3' UTR of *Elk-1* or *Myocd*




Figure 3 | miR-145 directs vascular smooth muscle cell fate.

a, Immunocytochemistry of 10T1/2 fibroblasts using smooth muscle (Sm) α -actin antibodies (red) under conditions indicated; nuclear stain, DAPI (blue). **b**, Quantification of Sm- α -actin positive cells ($n = 6$). **c**, qPCR of Sm gene expression in 10T1/2 fibroblasts transfected with Myocd with or without anti-miR-145 or **d**, in 10T1/2 fibroblasts transfected with 50 ng Myocd with or without miR-145 ($n = 5$). **e**, Western blot of calponin and Sm- α -actin. **f**, Left: immunocytochemistry of neural crest stem cells (Joma1.3 NCCs) with or without miR-145 using antibodies indicated

into the 3' UTR of a cytomegalovirus (CMV)-driven luciferase reporter. In the presence of the *Elk-1* 3' UTR, miR-143 repressed luciferase activity; this repression was diminished by mutation of one of the two miR-143 binding sites (Fig. 4a). The addition of an antagomir to inhibit miR-143 in the A10 rat aortic VSMC line resulted in upregulation of Elk-1 protein, but not mRNA, consistent with translational repression of Elk-1 by miR-143 (Fig. 4b, Supplementary Fig. 6b). Furthermore, inhibition of miR-143 caused a doubling of the proliferative rate of VSMCs, demonstrating the function of miR-143 in negatively regulating VSMC proliferation (Fig. 4c).

The presence of putative miR-145 binding sites in the *Myocd* 3' UTR seemed counter to the observed effects of miR-145 in potentiating Myocd's reprogramming effects. When we cloned the *Myocd* 3' UTR into a CMV-driven luciferase vector and introduced this into Cos cells, the constitutive luciferase activity decreased greater than 100-fold. Surprisingly, introduction of miR-145, but not miR-143, with the luciferase vector in Cos cells resulted in relief of the repression and an \sim 250-fold increase in luciferase activity compared to the CMV-luciferase-*Myocd* 3' UTR-luciferase vector alone (Fig. 4d). The increase in luciferase activity was largely lost on mutation of the miR-145 binding site in the *Myocd* 3' UTR (Fig. 4d). In contrast, introduction of the same CMV-luciferase-*Myocd* 3' UTR reporter did not cause a decrease in baseline luciferase activity in 293T epithelial cells. However, even in these cells, miR-145 consistently increased luciferase activity by \sim 1.5-fold (data not shown). Although antibodies to detect endogenous Myocd levels by western blot are not available, these findings are consistent with the recent observation that miRNAs can act as translational activators or repressors based on the state of the cell cycle⁶. Although the mechanism for this remains unclear, it will be

interesting to determine if miR-145 prevents binding of a repressive RNA-binding protein enriched in Cos cells. Although miR-145 may result in increased Myocd protein, its effects in potentiating Myocd-induced reprogramming of fibroblasts did not require the presence of its binding site in Myocd's 3' UTR. The potentiating effects of miR-145 could, however, be through effects on translation of endogenous *Myocd* mRNAs induced by the transfected Myocd protein; alternatively, miR-145 may also promote differentiation through targets independent of Myocd. Indeed, our bioinformatics approach identified potential miR-145 binding sites in several other positive regulators of smooth muscle proliferation, including Kruppel-like factor 4 (Klf4) and Calmodulin kinase II-delta (CamkII δ). Klf4 is a transcription factor involved in pluripotency³⁰ that is also rapidly induced in post-injury proliferating VSMCs, where it interacts with enhancers in smooth muscle growth genes, inhibits smooth muscle differentiation genes, and represses Myocd expression³¹. The miR-145 binding site in the 3' UTR of *Klf4* specifically mediated miR-145-dependent repression in luciferase assays (Fig. 4e and Supplementary Fig. 6c). Furthermore, knock-down of miR-145 in rat A10 VSMCs resulted in an increase in Klf4 protein levels, but no change in *Klf4* mRNA levels (Fig. 4f, Supplementary Fig. 6d). Similarly, a putative binding site in *CamkII- δ* , involved in multiple events including neointimal proliferation^{32,33}, was validated as a miR-145-repressed target by luciferase and western analysis in VSMCs (Fig. 4g, h and Supplementary Fig. 6e). Numerous predicted targets for both miRNAs that were not validated in luciferase assays are shown (Supplementary Fig. 6f, g).

Consistent with miR-145 repression of genes involved in VSMC proliferation, introduction of miR-145 was sufficient to suppress the




Figure 4 | miR-143 and miR-145 target a network of factors to promote VSMC differentiation and repress proliferation. **a**, Luciferase activity in Cos cells on introduction of *Elk-1* 3' UTR or mutant 3' UTR (mut) downstream of a CMV-driven luciferase reporter with indicated miRNAs ($n = 5$). **b**, *Elk-1* protein in cell lysates from A10 VSMCs transfected with a scrambled (scr) miRNA or anti-miR-143 or anti-miR-145 assessed by western blot. **c**, Proliferation of VSMCs on inhibition of miR-143 or miR-145 relative to control (5% FBS, $n = 5$). **d**, Luciferase activity in Cos cells with *Myocd* 3' UTR sequences with indicated miRNAs ($n = 5$). The *Myocd* binding site (BS) was mutated in the context of a 4× concatemer. **e**, Luciferase activity with WT or mutated *Klf4*-3' UTR upon introduction of indicated miRNAs ($n = 5$). **f**, Analysis of *Klf4* protein in cell lysates from A10 cells transfected with indicated anti-miRs by western blot. **g**, Luciferase activity of WT or mutated *CamkII-δ* 3' UTR ($n = 5$). **h**, Western analysis for *CamkII-δ* protein in A10 cells transfected with scr miRNA or anti-miR-145. **i**, Proliferation of VSMCs relative to control ($n = 5$). Error bars, s.d. Densitometry calculation performed by Image J. * $P < 0.05$.

proliferative response normally induced by platelet-derived growth factor (PDGF-β) in cultured VSMCs (Fig. 4i). In addition, lentiviral-mediated introduction of miR-145 into ligated mouse carotid arteries *in vivo* increased expression of markers of VSMC differentiation (for example, Calponin and Sm-α-actin), as well as *Myocd*, compared to control-infected injured carotid arteries (Supplementary Fig. 7). These findings suggest that miR-145 promotes VSMC differentiation by directly repressing numerous transcription factors that promote the proliferative state while stabilizing factors that promote the differentiated state of VSMCs (Fig. 5).

Discussion

The ability of miR-145 to efficiently direct VSMC differentiation from multipotent stem cells is the first evidence, to our knowledge, of a miRNA capable of directing the VSMC fate. This is consistent with its early expression in the aorta of developing embryos, as VSMC differentiation is initiated from neural crest and mesodermal progenitors. Once VSMC identity is established in the embryo, the downregulation of miR-143 and miR-145 in the developing embryo




Figure 5 | Model of miR-143 and miR-145 regulation of smooth muscle cell proliferation and differentiation. miR-143 and miR-145 are positively regulated by SRF and function to repress multiple factors that normally promote the less differentiated, more proliferative smooth muscle phenotype (lavender). These include *Klf4*, which interacts with SRF and also represses *Myocd*. miR-145 has a positive effect on *Myocd* activity to concurrently promote the more differentiated smooth muscle phenotype (peach), thereby also functioning to reinforce miR-145 and miR-143 expression. Effects of miR-145 and miR-143 converge on SRF-dependent transcription by regulation of co-activators and co-repressors to dictate the proliferative or differentiated phenotype of VSMCs. Dashed lines indicate indirect effects.

may allow necessary proliferation. Subsequent upregulation postnatally (coincident with the more differentiated VSMC state) and downregulation during neointimal hyperplasia indicate dynamic regulation that may contribute to the oscillating state of VSMCs. The observation that miR-145 is necessary and sufficient for VSMC differentiation raises the possibility that restoration of this miRNA could suppress the smooth muscle hyperplasia observed in vascular injury and atherosclerosis. Furthermore, the multiple targets we identified for miR-143 and miR-145 reveal an elegant mechanism by which this family of miRNAs promotes differentiation and simultaneously represses proliferation of VSMCs by converging on SRF-dependent co-activators and co-repressors (Fig. 5). Our findings suggest miR-145 promotes VSMC differentiation in part by increasing *Myocd* protein and functioning in a feed-forward reinforcement of its own expression by the SRF-*Myocd* complex, while miR-143 represses *Myocd*'s competitor, *Elk-1*. Given the potent effects on differentiation shown here, future studies will determine if restoration of normal levels of miR-143 and miR-145 holds therapeutic value in the setting of vascular disease.

The downregulation of miR-145 in numerous cancers and our findings that it promotes differentiation raises the possibility that miR-145 functions as a pro-differentiation factor in a lineage-specific fashion depending on the cellular context. The targeting of *Klf4* supports this notion, as *Klf4* is expressed in undifferentiated ES cells and in other less differentiated cell types. Recent evidence indicates that miR-145 represses *Klf4* in human ES cells as they begin to differentiate and is required for normal differentiation³⁴. As *Klf4* is one of four factors that together are sufficient to reprogram human fibroblasts into a pluripotent state (induced pluripotent stem cells)³⁰, it will be interesting to determine whether inhibition of miR-145 can enhance generation of pluripotent stem cells.

METHODS SUMMARY

Transgenic mice were generated by pronuclear injection and assayed by Blueo-gal (Invitrogen) staining as described⁷. Constructs contained promoter fragments cloned upstream of the pHsp68LacZ reporter. Embryonic hearts were collected at E9.5 from *Isl1-cre* mice¹⁹ crossed with *Rosa26-YFP* mice²⁰, and qPCR was performed from YFP⁺ cells. Electromobility shift assay (EMSA) was performed as described³⁵ using oligos corresponding to the conserved SRF-binding sites in

the miR-143/145 enhancer. To identify and validate putative miRNA target genes, we used an in-house automated algorithm^{7,10} and cloned the 3' UTR of each mRNA into the pMiR-Report luciferase reporter. Luciferase activity was measured using the Luciferase Dual-Reporter Kit. To assess miR-143/145 function, rat aortic A10 VSMCs or 10T1/2 fibroblasts were transfected with expression plasmids containing either pre-miR-145 or pre-miR-143, or inhibitors to miR-143 or -145, and then assayed for VSMC-marker gene expression by qPCR, western blot and immunocytochemistry. Myogenic conversion assays were performed as described³⁶ with 1–2 µg of Myocd. For multipotent stem cell studies, the JoMa1.3 neural crest cell line was maintained as reported²⁹. To induce VSMC differentiation, miR-145 was transiently transfected. A10 VSMCs proliferation studies were done as reported³⁷ using the CellTiter 96TM assay and miRNAs were transfected at varying concentrations; 5 ng ml⁻¹ of PDGF-β was added to appropriate wells post-growth arrest. Changes in intracellular calcium concentration ([Ca²⁺]_i) were measured using a calcium fluorescent dye, Indo-1 AM, as described³⁸ in A10 VSMCs or JoMa1.3 neural crest stem cells transfected with pre-miR-145 and exposed to 10 nM of the calcium agonist, endothelin-1, at 30 s to stimulate calcium flux³⁸. For assessment of miR-143 or miR-145 expression during vascular injury, ligated carotid arteries were collected from mice and sectioned, and aortic lesions from apolipoprotein E-null mice fed a western diet were dissected; subsequently, expression was analysed by qPCR and in-situ hybridization.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

Received 25 February; accepted 10 June 2009.
Published online 5 July 2009.

- Kloosterman, W. P. & Plasterk, R. H. The diverse functions of microRNAs in animal development and disease. *Dev. Cell* **11**, 441–450 (2006).
- Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. *Nature Rev. Cancer* **6**, 857–866 (2006).
- Zhao, Y. & Srivastava, D. A developmental view of microRNA function. *Trends Biochem. Sci.* **32**, 189–197 (2007).
- Bartel, D. P. MicroRNAs: target recognition and regulatory functions. *Cell* **136**, 215–233 (2009).
- Rajewsky, N. MicroRNA target predictions in animals. *Nature Genet.* **38** (Suppl), S8–S13 (2006).
- Vasudevan, S., Tong, Y. & Steitz, J. A. Switching from repression to activation: microRNAs can up-regulate translation. *Science* **318**, 1931–1934 (2007).
- Zhao, Y., Samal, E. & Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. *Nature* **436**, 214–220 (2005).
- Kwon, C., Han, Z., Olson, E. N. & Srivastava, D. MicroRNA1 influences cardiac differentiation in *Drosophila* and regulates Notch signaling. *Proc. Natl Acad. Sci. USA* **102**, 18986–18991 (2005).
- Chen, J. F. *et al.* The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nature Genet.* **38**, 228–233 (2006).
- Zhao, Y. *et al.* Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1–2. *Cell* **129**, 303–317 (2007).
- Ivey, K. N. *et al.* MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. *Cell Stem Cell* **2**, 219–229 (2008).
- Srivastava, D. Making or breaking the heart: from lineage determination to morphogenesis. *Cell* **126**, 1037–1048 (2006).
- Kattman, S. J., Huber, T. L. & Keller, G. M. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. *Dev. Cell* **11**, 723–732 (2006).
- Le Douarin, N. M., Creuzet, S., Couly, G. & Dupin, E. Neural crest cell plasticity and its limits. *Development* **131**, 4637–4650 (2004).
- Ross, R. The pathogenesis of atherosclerosis: A perspective for the 1990s. *Nature* **362**, 801–809 (1993).
- Owens, G. K., Kumar, M. S. & Wamhoff, B. R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol. Rev.* **84**, 767–801 (2004).
- Yoshida, T. & Owens, G. K. Molecular determinants of vascular smooth muscle cell diversity. *Circ. Res.* **96**, 280–291 (2005).
- Wang, Y., Medvid, R., Melton, C., Jaenisch, R. & Blelloch, R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. *Nature Genet.* **39**, 380–385 (2007).
- Cai, C. L. *et al.* Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev. Cell* **5**, 877–889 (2003).
- Srinivas, S. *et al.* Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev. Biol.* **1**, 4 (2001).
- Moretti, A. *et al.* Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell* **127**, 1151–1165 (2006).
- Wang, Z. *et al.* Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. *Nature* **428**, 185–189 (2004).
- Wang, D. *et al.* Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. *Cell* **105**, 851–862 (2001).
- Chen, J., Kitchen, C. M., Streb, J. W. & Miano, J. M. Myocardin: a component of a molecular switch for smooth muscle differentiation. *J. Mol. Cell. Cardiol.* **34**, 1345–1356 (2002).
- Long, X., Bell, R. D., Gerthoffer, W. T., Zlokovic, B. V. & Miano, J. M. Myocardin is sufficient for a smooth muscle-like contractile phenotype. *Arterioscler. Thromb. Vasc. Biol.* **28**, 1505–1510 (2008).
- Chen, C. Y. & Schwartz, R. J. Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac alpha-actin gene transcription. *Mol. Cell. Biol.* **16**, 6372–6384 (1996).
- Ji, R. *et al.* MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. *Circ. Res.* **100**, 1579–1588 (2007).
- Krutzfeldt, J. *et al.* Silencing of microRNAs *in vivo* with 'antagomirs'. *Nature* **438**, 685–689 (2005).
- Maurer, J. *et al.* Establishment and controlled differentiation of neural crest stem cell lines using conditional transgenesis. *Differentiation* **75**, 580–591 (2007).
- Takahashi, K. *et al.* Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861–872 (2007).
- Liu, Y. *et al.* Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. *J. Biol. Chem.* **280**, 9719–9727 (2005).
- House, S. J. & Singer, H. A. CaMKII-delta isoform regulation of neointima formation after vascular injury. *Arterioscler. Thromb. Vasc. Biol.* **28**, 441–447 (2008).
- Mishra-Gorur, K., Singer, H. A. & Castellot, J. J. Jr. Heparin inhibits phosphorylation and autonomous activity of Ca²⁺/calmodulin-dependent protein kinase II in vascular smooth muscle cells. *Am. J. Pathol.* **161**, 1893–1901 (2002).
- Xu, N., Papagiannakopoulos, T., Pan, G., Thomson, J. A. & Kosik, K. S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. *Cell* **137**, 647–658 (2009).
- Yamagishi, H. *et al.* Tbx1 is regulated by tissue-specific forkhead proteins through a common Sonic hedgehog-responsive enhancer. *Genes Dev.* **17**, 269–281 (2003).
- Wang, Z., Wang, D. Z., Pipes, G. C. & Olson, E. N. Myocardin is a master regulator of smooth muscle gene expression. *Proc. Natl Acad. Sci. USA* **100**, 7129–7134 (2003).
- Yamamoto, M. *et al.* The roles of protein kinase C beta I and beta II in vascular smooth muscle cell proliferation. *Exp. Cell Res.* **240**, 349–358 (1998).
- Sinha, S. *et al.* Assessment of contractility of purified smooth muscle cells derived from embryonic stem cells. *Stem Cells* **24**, 1678–1688 (2006).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Acknowledgements We thank R. Blelloch for DGCR8-null EBs; R.J. Schwartz for SRF-null ES cells; I. Charo and N. Saederup for RNA from atherosclerotic tissue; J. Maurer for JoMa neural crest cell line; L. Qian and Y. Huang for providing mouse cardiac infarct RNA; C. Tsou for help with calcium flux assays; E. N. Olson for the myocardin expression plasmid; P. Swinton for generation of transgenic mice; J. Fish and C. Miller for histopathology support; S. Orday and G. Howard for scientific editing; B. Taylor for manuscript preparation. We also thank members of the Srivastava laboratory for discussions. J.M.M. was supported by HL62572 and HL091168 from NHLBI/NIH. D.S. was supported by grants from the NHLBI/NIH and the California Institute for Regenerative Medicine (CIRM) and was an Established Investigator of the American Heart Association. This work was also supported by NIH/NCR grant CO6 RR018928 to the Gladstone Institutes.

Author Contributions K.R.C. and D.S. designed the study and K.R.C. executed or oversaw execution of all experiments; N.T.S. and E.C.B. performed the NCC studies; M.P.W. and K.N.I. performed some expression and stem cell studies and K.N.I. helped supervise the project; A.N.M. provided technical support; T.-H.L. and J.M.M. performed carotid artery ligation studies; S.U.M. isolated YFP⁺ progenitor cells and performed some expression studies; J.M.M. assisted K.R.C. and D.S. in editing the manuscript; K.R.C. and D.S. wrote the manuscript and D.S. supervised all aspects of the project.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details accompany the full-text HTML version of the paper at www.nature.com/nature. Correspondence and requests for materials should be addressed to D.S. (dsrivastava@gladstone.ucsf.edu).

METHODS

Transgenic mice and flow cytometry. Transgenic mice were generated and Bluogal staining and histological analyses were performed as described⁷. For promoter analysis, fragments were subcloned into a pHsp68LacZ reporter vector and injected into pronuclei. The 4.2-kb regulatory element corresponds to mouse chr 18:61809195-61813466. *Islet1-cre* mice¹⁹ were crossed with Rosa26-YFP mice²⁰, embryos were collected at E9.5, and heart and surrounding tissue were dissected, trypsinized, spun at ~300g and the pellet was resuspended in PBS and filtered through a 40- μ m Millipore membrane. Selection by FACS was based on expression of YFP. YFP⁺ cells were collected for RNA preparation.

miRNA qPCR and miRNA *in situ* hybridization. Total RNA was isolated (Trizol, Invitrogen) from mouse E9.5 embryonic hearts and used for quantitative real-time PCR. miRNA *in situ* hybridization analyses were performed as described³⁹ with the following modifications: paraffin-embedded tissue sections or cryosections were treated for 15 min with Proteinase K, hybridized at 59 °C (miR-145) or 42 °C (miR-143), and final colour development was performed with NBT/BCIP (Roche).

Electromobility shift assay (EMSA). Oligoribonucleotides corresponding to the conserved SRF-binding sites (underlined) and flanking nucleotides in the miR-143/145 enhancer were synthesized (Integrated DNA Technologies) as follows:

SRF binding site: GGGAGCAGCCTTGCCATATAAGGGCAGG; SRF mutant binding site: GGGAGCAGCCTTGCTACCGAAGGGCAGG. EMSA was performed as described³⁵.

miRNA target prediction. Putative miRNA target genes were identified using an in-house automated algorithm based on empirical miRNA:mRNA interaction data^{7,10} that qualifies mRNAs based on (1) complementarity between the seed region of the miRNA and the mRNA 3' UTR as annotated in RefSeq; (2) identification of an extended binding site; (3) favourable binding affinity between the miRNA and mRNA target site as calculated by RNAhybrid⁴⁰; (4) high free energy in the regions flanking the putative binding site as determined by mFold⁴¹; (5) absence of stabilizing elements in the binding site; (6) presence of destabilizing elements in the region surrounding and including the possible binding site; and (7) conservation over a number of species.

miR-143 and miR-145 target analyses and expression. A 250-bp fragment encompassing miR-145 was ligated into pSilencer 4.1-CMV (Ambion). A 250-bp fragment containing miR-143 was ligated into pEF-Dest-51 (Invitrogen). The entire 3' UTR of each mRNA containing predicted miR-143 and/or miR-145 binding sites was cloned into the pMiR-Report luciferase reporter (Applied Biosystems). All assays were performed in quadruplicate in 12-well plates of Cos cells transfected with siPort XP-1 (Ambion). After 24 h, cells were harvested and luciferase activity was measured with the Luciferase Dual-Reporter Kit (Promega). Renilla assays were performed in parallel to normalize for transfection efficiency.

Embryonic stem (ES) cells or embryoid bodies (EBs), A10 cells or differentiated 10T1/2 fibroblasts were harvested in Trizol (Invitrogen) for total RNA isolation. Total RNA (2 μ g) from each sample was reversed transcribed with Superscript III (Invitrogen). Taqman primers were used to amplify genes (ABI; primer sequences available upon request). The primers to detect the 1.7-kb miR-143/145 primary transcript were as follows: forward, GCATCTC TGGTCAGTTGGG; reverse, GACCTCAAGAACAGTAT. GAPDH was used as a control. *DGCR8*^{null} EBs (day 8, D10 EBs) were a gift from R. Blelloch¹⁸. miRNA qPCR on β -MHC-GFP control EBs, *SRF*^{null} EBs, or *SRF*^{null} EBs expressing miR-1 or miR-133 was performed as described above; miR-16 was used as the endogenous control. Each qPCR was performed at least three times; representative results are shown as fold expression relative to undifferentiated ES cells.

Tissue culture. 10T1/2 fibroblasts were maintained at low density (~30% confluence) in DMEM with 10% FBS and were transfected with Lipofectomine 2000 (Invitrogen) and 1–2 μ g of full length or smooth muscle isoform of Myocd³⁶. Pre-miR-145 sequence containing ~250 bp amplified from genomic DNA was cloned into pSilencer 4.1-CMV vector (Ambion) and pre-miR-143 was cloned into the pEF-Dest-51 vector (Invitrogen). Two days after transfection, media was replaced with differentiation media (DMEM, 2% horse serum). 4–5 days later, further analyses, including immunocytochemistry, western blot and RT-PCR were performed.

A10 VSMCs and Cos cells were maintained in DMEM with 10% FBS. A10 cells were transfected with BlockIT Fluorescent oligo (Invitrogen), miR-143 or miR-145 inhibitor (Dharmacon) or antagomiR (IDT Technologies), or miR-143, 145 mimic (Dharmacon). 24–48 h later, western blot or RT-PCR was performed.

The Joma1.3 neural crest cell line was maintained as reported²⁹. NCCs were plated (~7.5 \times 10⁵ cells per 10 cm²) on plastic culture dishes coated with fibronectin, and kept in an undifferentiated state by the addition of 200 nM 4-OHT (Tamoxifen) every 24 h. For differentiation into VSMCs, TGF- β was added 24 h after the last 4-OHT treatment, which was stopped to allow differentiation to take place within 4–6 days. Pre-miR-145 or -miR-143 was transfected in 6-well culture dishes using 10 μ l lipofectamine (Invitrogen) at concentrations ranging from 66 nM to 132 nM to induce VSMC differentiation 24 h after removal of 4-OHT.

Proliferation assays. Rat aortic A10 VSMCs proliferation studies were done as reported³⁷. Briefly, cells were plated at a density of 5,000 cells per well in 96-well plates containing 5% FBS/DMEM. After plating, miRNAs were transfected at varying concentrations ranging from 20 nM to 240 nM. Twelve hours later, media was washed three times and changed to serum free DMEM with antibiotics. Serum free conditions were maintained for 48 h to allow growth arrest. The medium was then changed to 5% FBS/DMEM and 5 ng ml⁻¹ of PDGF- β (R&D Systems) was added to appropriate wells. After 24 h, rates of proliferation were determined using the CellTiter 96TM assay (Promega). Proliferation was measured by the amount of 490 nm absorbance and is directly proportional to the number of living cells. Proliferation was subsequently expressed as absorbance of cells with treatment compared to cells without treatment. Each experiment was done in quintuplicate.

Immunohistochemistry and western blot analysis. Immunostaining was performed using pre-ready mouse anti-smooth muscle actin (Dako, 1A4), 1:500 mouse anti-caldesmon (Abcam, 12B5), and 1:50 rabbit anti-calponin (Chemicon) antibodies and 1:400 Tritc- or Fitc-conjugated goat anti-mouse IgG or goat anti-rabbit IgG (Jackson ImmunoResearch). Myogenic conversion assays were performed as described, and protein lysates collected³⁶. Rat aortic A10 cells were collected and assayed using Elk-1, Klf-4, and CamKII- δ antibodies (Cell Signaling).

Calcium flux assays. Calcium studies were performed as described³⁸. In brief, rat aortic smooth muscle cells or JoMa1.3 NCCs transfected with pre-miR-145 were grown to 95% confluency, and resuspended in medium containing 1 mg ml⁻¹ BSA and 10 mM HEPES to make 1 \times 10⁷ cells ml⁻¹. Then the cells were loaded with cell-permeant Indo-1 AM (Invitrogen) for 40 min at 37 °C, and subsequently washed and resuspended with Hank's buffered saline solution containing 1 mg ml⁻¹ BSA and 10 mM HEPES. Indo-1 was excited at 350 nm and measured at 410 and 490 nm. The fluorescence intensity ratio (F_{410nm}/F_{490nm}) was calculated using a Hitachi F-2000 fluorescent spectrophotometer and Intracellular Cation Measurement System software, version 1.03 (Hitachi). Cells were exposed to 10 nM of the calcium agonist, endothelin-1 (Sigma) at 30 s to stimulate calcium flux³⁸.

Mouse vascular injury and atherosclerosis models. Mice that had their left carotid artery ligated were killed 21 days post ligation, fixed and sectioned to obtain cross-sections of the left carotid artery as described⁴²; the contralateral right carotid artery was used for control. Pre-packaged pCDH-CMV-MCS-EF1-copGFP control or pre-miR-145 lentivirus (1 \times 10⁷ infectious units, System Biosciences) was mixed in 20% pluronic gel and kept cold before application to 12-week-old FVB/NJ mice. Lentiviral-pluronic gel was immediately applied to the external surface of the ligated vessel following arterial injury. Nine days post-ligation, the proximal portion of the injured carotid artery was rapidly removed for total RNA isolation (Trizol) and qPCR (BioRad, MyQ) analysis. 12-week-old apolipoprotein (Apo) E-null mice were fed a Western diet for 4 weeks, and aortic lesions were dissected and collected for RNA analysis.

Statistical analysis. The two-tailed Student's *t*-test, type II, was used for data analysis. *P* < 0.05 was considered significant.

39. Obernosterer, G., Martinez, J. & Alenius, M. Locked nucleic acid-based *in situ* detection of microRNAs in mouse tissue sections. *Nature Protocols* 2, 1508–1514 (2007).
40. Kruger, J. & Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. *Nucleic Acids Res.* 34, W451–W454 (2006).
41. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* 31, 3406–3415 (2003).
42. Regan, C. P., Adam, P. J., Madsen, C. S. & Owens, G. K. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. *J. Clin. Invest.* 106, 1139–1147 (2000).